Atopic dermatitis (AD), also known as eczema, is one of the most common inflammatory skin disorders worldwide, with an increasing incidence in the last few decades, especially in developed countries. In recent years, the underlying molecular basis for AD has been increasingly characterized, particularly surrounding barrier dysfunction, cutaneous and systemic immune abnormalities, and the role of the microbiome. This has led to the development of new targeted therapies and improved treatment methods for this challenging disease.
Our ALLEVIATE Atopic Dermatitis Initiative is an online CME tool that aims to provide clinicians with new strategies to improve standards of care for AD. Our goals are multifold:
Thank you for visiting us today. We welcome you to our website and invite you to explore the link below for information on AD for clinicians and patients.